Latest News
September 16, 2021
Not intended for U.S. and UK Media – ESMO Congress 2021:
Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer
August 31, 2021
Not intended for U.S. and UK Media
Bayer starts Phase III clinical development program OASIS with Elinzanetant
August 28, 2021
Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021
New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression
Our Stories
